Oxbow Advisors LLC boosted its position in shares of Pfizer, Inc. (NYSE:PFE) by 1.0% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 350,192 shares of the biopharmaceutical company’s stock after buying an additional 3,515 shares during the period. Pfizer accounts for about 2.1% of Oxbow Advisors LLC’s portfolio, making the stock its 7th largest holding. Oxbow Advisors LLC’s holdings in Pfizer were worth $11,763,000 at the end of the most recent reporting period.
A number of other large investors have also recently bought and sold shares of PFE. Chevy Chase Trust Holdings Inc. boosted its holdings in shares of Pfizer by 0.9% during the 1st quarter. Chevy Chase Trust Holdings Inc. now owns 5,428,710 shares of the biopharmaceutical company’s stock worth $185,715,000 after purchasing an additional 46,366 shares during the last quarter. Peachtree Investment Advisors Inc. boosted its holdings in shares of Pfizer by 1.3% during the 1st quarter. Peachtree Investment Advisors Inc. now owns 7,516 shares of the biopharmaceutical company’s stock worth $257,000 after purchasing an additional 100 shares during the last quarter. Atlas Brown Inc. boosted its holdings in shares of Pfizer by 13.1% during the 1st quarter. Atlas Brown Inc. now owns 35,471 shares of the biopharmaceutical company’s stock worth $1,213,000 after purchasing an additional 4,096 shares during the last quarter. Pure Financial Advisors Inc. boosted its holdings in shares of Pfizer by 0.4% during the 1st quarter. Pure Financial Advisors Inc. now owns 22,091 shares of the biopharmaceutical company’s stock worth $756,000 after purchasing an additional 84 shares during the last quarter. Finally, Manning & Napier Advisors LLC boosted its holdings in shares of Pfizer by 5.2% during the 1st quarter. Manning & Napier Advisors LLC now owns 719,433 shares of the biopharmaceutical company’s stock worth $24,610,000 after purchasing an additional 35,433 shares during the last quarter. Institutional investors own 69.09% of the company’s stock.
COPYRIGHT VIOLATION WARNING: This piece was published by Ticker Report and is the sole property of of Ticker Report. If you are accessing this piece on another website, it was illegally copied and reposted in violation of international trademark & copyright legislation. The correct version of this piece can be accessed at https://www.tickerreport.com/banking-finance/2886991/oxbow-advisors-llc-boosts-holdings-in-pfizer-inc-pfe.html.
Pfizer, Inc. (NYSE PFE) traded up 2.608% on Tuesday, reaching $35.215. The company’s stock had a trading volume of 23,905,353 shares. The firm has a 50 day moving average price of $33.35 and a 200 day moving average price of $33.48. The stock has a market capitalization of $209.44 billion, a P/E ratio of 25.761 and a beta of 1.00. Pfizer, Inc. has a 52 week low of $29.83 and a 52 week high of $35.75.
Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, August 1st. The biopharmaceutical company reported $0.67 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.65 by $0.02. The company had revenue of $12.90 billion for the quarter, compared to analyst estimates of $13.08 billion. Pfizer had a net margin of 15.84% and a return on equity of 24.51%. Pfizer’s revenue for the quarter was down 1.9% on a year-over-year basis. During the same quarter last year, the business earned $0.64 EPS. On average, equities analysts anticipate that Pfizer, Inc. will post $2.56 EPS for the current year.
The business also recently declared a quarterly dividend, which was paid on Friday, September 1st. Shareholders of record on Friday, August 4th were issued a $0.32 dividend. The ex-dividend date of this dividend was Wednesday, August 2nd. This represents a $1.28 dividend on an annualized basis and a dividend yield of 3.73%. Pfizer’s dividend payout ratio (DPR) is presently 94.12%.
Several research analysts have recently weighed in on the company. BidaskClub upgraded Pfizer from a “strong sell” rating to a “sell” rating in a report on Friday, June 23rd. BMO Capital Markets restated a “buy” rating and set a $37.00 target price on shares of Pfizer in a report on Wednesday, September 6th. Credit Suisse Group cut Pfizer from an “outperform” rating to a “neutral” rating and lowered their target price for the stock from $38.00 to $36.00 in a report on Thursday, July 20th. Sanford C. Bernstein set a $39.00 target price on Pfizer and gave the stock a “buy” rating in a report on Monday, July 17th. Finally, Cowen and Company set a $43.00 target price on Pfizer and gave the stock a “buy” rating in a report on Monday, July 10th. Two equities research analysts have rated the stock with a sell rating, eleven have given a hold rating and ten have issued a buy rating to the stock. The company currently has a consensus rating of “Hold” and an average price target of $37.61.
In other Pfizer news, CEO Ian C. Read sold 197,168 shares of Pfizer stock in a transaction on Thursday, August 31st. The shares were sold at an average price of $34.00, for a total value of $6,703,712.00. Following the transaction, the chief executive officer now owns 580,318 shares in the company, valued at approximately $19,730,812. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CEO Ian C. Read sold 96,950 shares of Pfizer stock in a transaction on Friday, August 4th. The shares were sold at an average price of $34.00, for a total transaction of $3,296,300.00. The disclosure for this sale can be found here. In the last quarter, insiders sold 426,291 shares of company stock worth $14,475,911. 0.06% of the stock is owned by company insiders.
Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer, Inc. (NYSE:PFE).
Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with MarketBeat.com's FREE daily email newsletter.